Login to Your Account

Theraclone, MD Anderson target super-responders in IO start-up

By Marie Powers
News Editor

Wednesday, October 7, 2015

Theraclone Sciences Inc. and the University of Texas MD Anderson Cancer Center broadened an informal immuno-oncology (IO) relationship in a big way, jointly launching Oncoresponse Inc. to discover and advance therapeutic antibodies against targets identified during the treatment of cancer patients receiving the IO regimens.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription